← Search & browse all drugs
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES › Somatropin and somatropin agonists
tesamorelin
H01AC06
Forms & Strengths
- Injectable powder for reconstitution: 1 mg/vial
- Injectable powder for reconstitution: 2 mg/vial
Adult Dosing
- 2 mg subcutaneously once daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy
Mechanism of Action
- Synthetic analog of growth hormone-releasing factor (GRF)
- Stimulates pituitary synthesis and pulsatile release of endogenous growth hormone (GH)
- Increases insulin-like growth factor-1 (IGF-1) levels to reduce visceral adipose tissue
Contraindications
- Hypersensitivity to tesamorelin or mannitol
- Hypothalamic or pituitary gland dysfunction, pituitary tumor, or hypophysectomy
- Active malignancy
- Pregnancy
Adverse Reactions
- Arthralgia
- Injection site reactions (pain, erythema, pruritus)
- Peripheral edema
- Paresthesia
- Myalgia
- Elevated glucose and HbA1c
- Hypersensitivity reactions
Drug Interactions
- Glucocorticoids may inhibit the growth hormone-releasing effects of tesamorelin
- Drugs metabolized by CYP450 enzymes (clearance of compounds may be altered due to changes in IGF-1 levels)
Curated Content: Needs Vetting Before Put to Clinical Use